The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.
Hugo Ford
Research Funding - Sanofi
Andrea Marshall
No relevant relationships to disclose
Jonathan Wadsley
No relevant relationships to disclose
Fareeda Y. Coxon
No relevant relationships to disclose
Wasat Mansoor
No relevant relationships to disclose
John A. Bridgewater
No relevant relationships to disclose
Srinivasan Madhusudan
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Gary William Middleton
Consultant or Advisory Role - Sanofi
Daniel Swinson
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Joyce Thompson
No relevant relationships to disclose
Jane M. Blazeby
No relevant relationships to disclose
David Cunningham
Research Funding - Sanofi
Paula Kareclas
No relevant relationships to disclose
Janet A. Dunn
No relevant relationships to disclose